Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 444

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Open access
Weiskopf, Kipp, Jahchan, Nadine S., Schnorr, Peter J., Cristea, Sandra, Ring, Aaron M., Maute, Roy L., Volkmer, Anne K., Volkmer, Jens-Peter, Liu, Jie, Lim, Jing Shan, Yang, Dian, Seitz, Garrett, Nguyen, Thuyen, Wu, Di, Jude, Kevin, Guerston, Heather, Barkal, Amira, Trapani, Francesca, George, Julie, Poirier, John T., Gardner, Eric E., Miles, Linde A., de Stanchina, Elisa, Lofgren, Shane M., Vogel, Hannes, Winslow, Monte M., Dive, Caroline, Thomas, Roman K., Rudin, Charles M., van de Rijn, Matt, Majeti, Ravindra, Garcia, K. Christopher, Weissman, Irving L., Sage, Julien·2016·Journal of Clinical Investigation

Abstract

Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited treatment options. CD47 is a cell-surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPα), which serves as an inhibitory receptor on macrophages. Here, we found that CD47 is highly expressed on the surface of human SCLC cells; therefore, we investigated CD47-blocking immunotherapies as a potential approach for SCLC treatment. Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture. In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47 gene markedly inhibited SCLC tumor growth. Furthermore, using comprehensive antibody arrays, we identified several possible therapeutic targets on the surface of SCLC cells. Antibodies to these targets, including CD56/neural cell adhesion molecule (NCAM), promoted phagocytosis in human SCLC cell lines that was enhanced when combined with CD47-blocking therapies. In light of recent clinical trials for CD47-blocking therapies in cancer treatment, these findings identify disruption of the CD47/SIRPα axis as a potential immunotherapeutic strategy for SCLC. This approach could enable personalized immunotherapeutic regimens in patients with SCLC and other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci81603

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 444

Metadata

Authors
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., Yang, D., Seitz, G., Nguyen, T., Wu, D., Jude, K., Guerston, H., Barkal, A., Trapani, F., George, J., Poirier, J. T., Gardner, E. E., Miles, L. A., de Stanchina, E., Lofgren, S. M., Vogel, H., Winslow, M. M., Dive, C., Thomas, R. K., Rudin, C. M., van de Rijn, M., Majeti, R., Garcia, K. C., Weissman, I. L., & Sage, J.
Venue
Journal of Clinical Investigation
Published
2016-06-13
Volume
126
Issue
7
Pages
2610-2620
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2414840542
Cited by
444
References
53
FWCI
15.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. https://app.cochat.ai/papers/10.1172/jci81603
The paper
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., Yang, D., Seitz, G., Nguyen, T., Wu, D., Jude, K., Guerston, H., Barkal, A., Trapani, F., George, J., . . . Sage, J. (2016). CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci81603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.